ALK2 inhibitors(Activin receptor type-1 inhibitors), CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors)

Therapeutic Areas

Hemic and Lymphatic DiseasesOther DiseasesNeoplasms+ [3]

Active Indication

Post-essential thrombocythemia myelofibrosisPost-polycythemia vera myelofibrosisPrimary Myelofibrosis+ [9]

Inactive Indication

Acute Myeloid LeukemiaAdult Acute Myeloblastic LeukemiaAggressive-Phase Chronic Myelocytic Leukemia+ [10]

Originator Organization

CTI BioPharma Corp.

Active Organization

Swedish Orphan Biovitrum ABSobi, Inc.

CTI BioPharma Corp.

+ [1]

Inactive Organization

S*BIO Pte Ltd.

Baxalta, Inc.

License Organization

Baxalta Bioscience India Pvt Ltd.

CTI BioPharma Corp.

Onyx Pharmaceuticals, Inc.

+ [3]

Drug Highest PhaseApproved

First Approval Date

United States (28 Feb 2022),

Primary MyelofibrosisThrombocytopenia

RegulationPriority Review (United States), Accelerated Approval (United States), Orphan Drug (United States), Fast Track (United States)

Structure/Sequence

Molecular FormulaC28H32N4O3

InChIKeyHWXVIOGONBBTBY-ONEGZZNKSA-N

CAS Registry937272-79-2

Clinical Trials associated with Pacritinib

NCT07226713

/ Not yet recruitingPhase 2IIT

A Single-Arm, Open-label, Phase II Study Evaluating Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors - (POSTPONE)

This is a single-arm, open-label phase 2 study to evaluate the role of pacritinib for patients with metastatic castrate-resistant prostate cancer that have progressed on ARSI. Patients will receive pacritinib 200 mg twice daily. To be eligible, patients must have a biopsy of a metastatic site within 30 days of treatment that demonstrates positive STAT5 activation status

Start Date01 Jul 2026

Sponsor / Collaborator

Medical College of Wisconsin

NCT07387354

/ Not yet recruitingPhase 1/2IIT

A Phase 1/2 Study of Pacritinib in Combination With Azacitidine for the Treatment of IPSS-M Moderate Low to Very High Risk Myelodysplastic Syndrome

This study will be conducted as a phase 1/2 study of safety and preliminary efficacy of pacritinib in combination with azacitidine for IPSS-M moderate low to very high risk MDS. Phase one will be a 3 + 3 design to assess the dose for the phase two portion. The phase two portion will employ a simon min-max two-stage design whereby fifteen patients will be enrolled in the first stage then ten more if at least two patients in stage one have a response. The dosing of pacritinib for the phase two study will be based on the phase one findings. Standard dosing of azacitidine will be used. A correlative study will be conducted in conjunction with the trial where the investigators will measure whole blood collected pre-treatment and at four days post-treatment to measure intracellular flow and phosflow to detect JAK/STAT, NF-κβ, and AKT/mTOR signaling in patient samples and how treatment affects these pathways.

Start Date01 Jul 2026

Sponsor / Collaborator

Thomas Jefferson University

[+1]

NCT06303193

/ RecruitingPhase 1/2IIT

Phase I/II Trial of Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

Background:
Myelodysplastic syndrome (MDS) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN) are blood disorders that can cause serious complications in children and adults. MDS and MDS/MPN can also progress to acute myeloid leukemia. Treatments for these disorders are risky and not always effective. Better treatments are needed.
Objective:
To test a study drug (pacritinib) in adults and children with MDS or MDS/MPN.
Eligibility:
Children (aged 12 to 17 years) and adults (aged 18 years and older) with MDS or MDS/MPN.
Design:
Participants will be screened. They will have a physical exam with blood tests. They will have tests of their heart function. They may have a bone marrow biopsy: An area over the hip will be numbed; a needle will be inserted to remove a sample of soft tissue from inside the hipbone.
Pacritinib is a capsule taken by mouth. All participants will take the study drug 2 times a day, every day, in 28-day cycles. They will write down the date and time they take each capsule. Doctors will assign varying dosages of the drug to different participants.
Participants will have clinic visits each week during cycle 1; every 2 weeks during cycle 2; and gradually increasing to every 3 months after cycle 13. Treatment will continue for up to 8 years.
Bone marrow biopsies, heart tests, and other tests will be repeated at intervals throughout the study. Participants will also fill out questionnaires about their quality of life, the symptoms of their disease, and other topics.

Start Date14 Jun 2026

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with Pacritinib

100 Translational Medicine associated with Pacritinib

100 Patents (Medical) associated with Pacritinib

245

Literatures (Medical) associated with Pacritinib

01 May 2026·Blood neoplasia

Comparison of the enzymatic and cellular profiles of clinical JAK inhibitors for the treatment of myelofibrosis

Article

Author: Drake, Katherine ; Katiyar, Kamna ; Margulis, Alex ; Trivedi, Gaurang ; Smith, Amanda ; Covington, Maryanne ; Laranjeira, Angelo Brunelli Albertoni ; Zhang, Guofeng ; Macarrón, Ricardo ; Zolotarjova, Nina ; Wass, Brittney ; Celik, Hamza

Four Janus kinase inhibitors (JAKinibs), ruxolitinib, fedratinib, pacritinib, and momelotinib, are indicated for myelofibrosis. All inhibit JAK2, but effects on additional kinases vary markedly, shaping their specific clinical pharmacology. Published comparative inhibitory profiles and cellular pharmacology data are incomplete and were determined here. Inhibitory potency and relative selectivity of JAKinibs were determined by full kinome profiling. JAKinib effects on signaling and cell growth were measured using JAK2-dependent and JAK2-independent cell lines. Ruxolitinib was the most potent JAK2 inhibitor (half-maximal inhibitory concentration [IC₅₀] at physiological [1mM] ATP, 2.9nM), followed by fedratinib (17nM), momelotinib (29nM), and pacritinib (39nM), and the most selective. The other JAKinibs inhibited multiple additional kinases beyond the few typically reported for each drug in the literature. Interestingly, pacritinib and momelotinib showed only modest activin A receptor type 1 (ACVR1) inhibition at clinical doses and physiological ATP concentrations, suggesting the role of ACVR1 inhibition in mediating their anemia-related benefits may be overestimated. The observed inhibitory levels are unlikely to translate to a clinically meaningful reduction in hepcidin levels. In JAK2-dependent cellular assays, ruxolitinib showed most potent inhibition of STAT5 phosphorylation (IC_50, 14nM), followed by momelotinib (201nM), pacritinib (421nM), and fedratinib (669nM), and was the only JAKinib that had minimal impact on growth in JAK2-independent cell lines. In conclusion, ruxolitinib was the most potent, and selective JAKinib with no relevant effects in JAK2-independent cells. In contrast, fedratinib, pacritinib, and momelotinib inhibited many other kinases and inhibited cell growth by JAK2-unrelated mechanisms at clinically relevant concentrations.

16 Apr 2026·Leukemia & Lymphoma

Pacritinib in patients with myelodysplastic/myeloproliferative neoplasms

Article

Author: Zargari, Michael ; Fedorov, Kateryna ; Mohan, Sanjay R. ; Canonico, Michael ; Ball, Somedeb ; Savona, Michael R. ; Walsh, Katherine J. ; Kishtagari, Ashwin ; Patel, Parth C. ; Nayak, Nanda

03 Apr 2026·EXPERT OPINION ON INVESTIGATIONAL DRUGS

Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management?

Review

Author: Otoukesh, Salman ; Ali, Haris ; Jamil, M. Abdullah

INTRODUCTION:

Graft-versus-host disease (GVHD) remains the primary barrier to successful allogeneic hematopoietic cell transplantation, contributing significantly to non-relapse mortality. With approximately 50% of patients developing GVHD despite prophylaxis, there is an urgent need for effective alternatives. Janus kinase (JAK) inhibitors have emerged as a promising class of targeted immunomodulators to address this clinical challenge.

AREAS COVERED:

This review examines the mechanistic rationale for JAK inhibition in GVHD and summarizes key preclinical and clinical data. We evaluate the efficacy and safety of selective and nonselective agents, including ruxolitinib, baricitinib, itacitinib, pacritinib, and rovadicitinib. Furthermore, the review analyzes recent advancements in peri-transplant prophylaxis, biomarker-driven strategies, and the comparative landscape of FDA-approved therapies for acute and chronic GVHD.

EXPERT OPINION:

The future of GVHD management is shifting from broad immunosuppression toward precision medicine. We anticipate a transition from the current 'steroid-first' paradigm to risk-stratified algorithms utilizing biomarker profiling and novel combination strategies. While ruxolitinib is the current cornerstone, the development of highly selective inhibitors and the resolution of financial access barriers will be crucial for establishing JAK inhibitors as the frontline standard of care over the next decade.

News (Medical) associated with Pacritinib

24 Mar 2026

·allsci.com

Karyopharm’s sNDA for Xpovio in myelofibrosis uncertain after mixed Phase III data

Karyopharm Therapeutics (Nasdaq: KPTI) reported topline results from its Phase III SENTRY trial in myelofibrosis, showing that Xpovio (selinexor) combined with ruxolitinib nearly doubled the rate of spleen volume reduction compared to ruxolitinib alone, though the combination failed to separate from the comparator on symptom improvement. The mixed outcome on co-primary endpoints sets up a complex regulatory discussion for the Newton, Massachusetts-based company, which plans to meet with the FDA to explore a potential supplemental new drug application. Trial specifics The SENTRY trial (XPORT-MF-034; NCT04562389) is a randomized, double-blind, placebo-controlled Phase III study that enrolled 353 JAK inhibitor–naïve myelofibrosis patients with platelet counts above 100 × 10⁹/L. Patients were randomized 2:1 to receive 60 mg selinexor once weekly plus ruxolitinib or placebo plus ruxolitinib. The trial had two co-primary endpoints: spleen volume reduction of 35% or more (SVR35) at week 24, and mean change in absolute total symptom score (Abs-TSS) over 24 weeks relative to baseline. Data are reported as of a February 20, 2026 cut-off. On the first co-primary endpoint, 50% of patients in the combination arm achieved SVR35 at week 24 compared to 28% with ruxolitinib alone (one-sided p<0.0001). Spleen responses appeared early, with 49% of combination-arm patients reaching SVR35 by week 12 versus 20% in the control arm, and were sustained at week 36 (47% versus 23%). On the second co-primary endpoint, however, the trial did not reach statistical significance: patients receiving selinexor plus ruxolitinib reported a 9.89-point improvement in Abs-TSS versus a 10.86-point improvement with ruxolitinib alone. Both arms achieved similar symptom relief relative to baseline, meaning the addition of selinexor did not confer a detectable symptom benefit over ruxolitinib monotherapy. An exploratory overall survival analysis yielded a hazard ratio of 0.43 (95% CI [0.19, 1.00]; nominal one-sided p=0.0222), suggesting a reduction in risk of death with the combination. The company noted these data are immature and intends to continue follow-up. A pre-specified exploratory endpoint examining variant allele frequency (VAF) reduction showed 32% of combination-arm patients achieving 20% or greater VAF reduction for driver mutations (JAK2, MPL, CALR) at week 24, compared to 24% with ruxolitinib alone (n=261). Other secondary endpoints, including progression-free survival, hemoglobin stabilization, and bone marrow fibrosis improvement, showed no meaningful difference between arms at the data cut-off. The safety profile was consistent with the known effects of both agents. Development context Selinexor is a first-in-class oral inhibitor of exportin 1 (XPO1), a nuclear transport protein responsible for shuttling tumor suppressor proteins and growth regulators out of the nucleus. By blocking XPO1, selinexor forces retention of these proteins in the nucleus, restoring their function and inducing cell death in malignant cells. This mechanism is distinct from JAK pathway inhibition, and the rationale for combining selinexor with ruxolitinib rests on targeting complementary biological pathways in myelofibrosis. The molecule was first approved in 2019 for relapsed/refractory multiple myeloma, and in 2020 for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The spleen volume reduction rate of 50% at week 24 in the combination arm compares to historical SVR35 rates for ruxolitinib monotherapy observed in the COMFORT trials, though the 28% rate in SENTRY’s control arm fell below those benchmarks. Cross-trial comparisons are limited by differences in study design, patient selection, and duration. Within the SENTRY trial itself, the internal comparison is more interpretable, and the near-doubling of SVR35 at week 12 (49% versus 20%) suggests the combination accelerates spleen response. Whether this translates into durable clinical benefit remains to be established as survival and other endpoints mature. The myelofibrosis treatment landscape remains anchored by JAK inhibitors. Ruxolitinib, approved by the FDA in 2011, is the standard frontline therapy. Fedratinib, pacritinib, and momelotinib have since received approval, each addressing specific patient subpopulations defined by platelet counts or anemia burden. Definitive randomized frontline OS benefit remains difficult to establish in MF, particularly given crossover in prior studies. That means the immature OS signal from SENTRY is a point of interest, though the wide confidence interval spanning 1.00 warrants caution. The field has seen several combination strategies struggle to show clear added benefit over JAK inhibitor monotherapy The regulatory path forward for Karyopharm is uncertain. Meeting one co-primary endpoint while missing the other creates ambiguity, and the FDA’s willingness to consider an sNDA based on SVR35 alone, alongside immature survival data, will depend on the agency’s assessment of the totality of evidence. The company stated it plans to present additional data at an upcoming medical meeting and submit a manuscript for peer-reviewed publication, with potential compendia inclusion anticipated in the second half of 2026. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Clinical ResultPhase 3Drug Approval

04 Mar 2026

·allsci.com

Sanofi acquires global rights to rovadicitinib from Sino Biopharmaceutical in up to USD 1.53b deal

Chia Tai Tianqing Pharmaceutical Group Co., Ltd (CTTQ), a subsidiary of Hong Kong-listed Sino Biopharmaceutical Limited (HKEX: 1177), entered into an exclusive license agreement with French giant Sanofi S.A. (Euronext: SAN). The deal confers global development, manufacturing, and commercialization rights to Sanofi in relation to Chia Tai’s rovadicitinib, a first-in-class oral small-molecule JAK/ROCK dual-target inhibitor, a molecule already approved and marketed in China under the brand name Anxu. The deal carries a total potential value of up to USD 1.53 billion, with Sino Bio eligible to receive an upfront payment of USD 135 million, plus development, regulatory, and sales milestone payments of up to USD 1.395 billion. Sanofi will also pay up to double-digit tiered royalties on annual net sales. Deal context Rovadicitinib is a dual inhibitor of the JAK/STAT and ROCK signaling pathways. By targeting JAK, the molecule suppresses inflammatory cytokine signaling from myeloid cells. Concurrent ROCK inhibition modulates STAT3/STAT5 phosphorylation, downregulating overactivated Th17 cells and enhancing regulatory T cell function to restore immune homeostasis. This dual mechanism produces synergistic anti-inflammatory and anti-fibrotic effects. Chi Tai secured a first approval for rovadicitinib in China in February 2026, indicated as a first-line treatment for adult patients with intermediate-2 or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF). In chronic graft-versus-host disease (cGVHD), the molecule has advanced to Phase III in China, where it received Breakthrough Therapy Designation from the CDE in August 2025. In the US, rovadicitinib has been cleared to conduct Phase II clinical studies in cGVHD. Phase Ib/IIa data published in Blood demonstrated superior 12-month failure-free survival and enhanced responses in fibrosis-dominated organs compared to other approved therapies, along with potential to overcome ruxolitinib resistance. For Sanofi, the deal is the latest in a string of in-licensing from Chinese innovators, including an August 2022 collaboration with Innovent Biologics on oncology assets and a March 2022 agreement with Adagene valued at up to approximately USD 2.5 billion for masked antibody technology. Sanofi also acquired Kadmon Holdings in 2021, gaining belumosudil (Rezurock), an approved selective ROCK2 inhibitor for cGVHD. The addition of rovadicitinib, a JAK/ROCK inhibitor, complements belumosudil’s ROCK-only mechanism in the same indication. The rovadicitinib JAK ROCK inhibitor enters a competitive landscape shaped by several approved agents. In myelofibrosis, Incyte’s ruxolitinib (Jakafi), a JAK1/JAK2 inhibitor licensed to Novartis for ex-US rights under a 2009 deal, remains the standard of care. Bristol Myers Squibb markets fedratinib (Inrebic), a JAK2 inhibitor, and CTI BioPharma’s pacritinib, acquired by SOBI in 2023, targets JAK2/FLT3 in patients with thrombocytopenia. In cGVHD specifically, Sanofi’s own belumosudil and Incyte’s ruxolitinib hold approvals. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Drug ApprovalLicense out/inPhase 2Breakthrough TherapyAcquisition

05 Dec 2025

·www.prnewswire.com

Sobi to Showcase Scientific advances and Commitment to Haematology at ASH 2025

STOCKHOLM, Dec. 5, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced its participation at the 65th American Society of Hematology (ASH) Annual Meeting, taking place on 6 – 9 December in Orlando, Florida. At this year's meeting, Sobi will showcase its commitment to advancing care in haematology with 19 scientific abstracts, including two oral presentations. These feature the most recent clinical data and insights from completed and ongoing studies across Sobi's innovative portfolio including data from efanesoctocog alfa, pegcetacoplan, avatrombopag, emapalumab, and pacritinib. These presentations underscore Sobi's mission to deliver life-changing therapies for patients with rare and severe blood disorders. "We will present evidence at ASH from a post hoc analysis demonstrating that pacritinib reduces or stabilises spleen size, improves haematologic parameters, and lessens myelofibrosis symptoms in patients with highrisk disease. These findings matter because they address key drivers of morbidity which affect daytoday functioning and quality of life. The ASH meeting also offers an opportunity to discuss the latest research on emapalumab, efanesoctocog alfa, pegcetacoplan, avatrombopag, as well as loncastuximab tesirine," said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi. Summary of full Sobi data to be presented at ASH 2025: Overview of treatment advances with complement Inhibitors in patients with Paroxysmal Nocturnal Haemoglobinuria. Optimising PNH treatment with the complement inhibitor Pegcetacoplan: A case report. User experience with Pegcetacoplan on-body Injector in patients with Paroxysmal Nocturnal Hemoglobinuria. About ALTUVOCT ® (efanesoctocog alfa) ALTUVOCT ® (efanesoctocog alfa) is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A (HA). ALTUVOCT can be used for all age groups and any disease severity. About the Sobi and Sanofi Collaboration Sobi and Sanofi collaborate on the development and commercialisation of ALTUVOCT® (efanesoctocog alfa), or ALTUVIIIO™ in the US. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe, North Africa, Russia, and most Middle Eastern markets). Sanofi has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory. About Aspaveli®/Empaveli® (pegcetacoplan) Aspaveli/Empaveli (pegcetacoplan) is a targeted C3 and C3b inhibitor designed to regulate excessive activation of the complement cascade, part of the body's immune system, which can lead to the onset and progression of many serious diseases. Aspaveli/Empaveli is approved for the treatment of adults with paroxysmal nocturnal haemoglobinuria (PNH) in the US, European Union, and other countries globally, and for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in the United States. It is under regulatory review for C3G and primary IC-MPGN in the European Union and other countries globally. About the Sobi and Apellis Collaboration Apellis and Sobi have global co-development rights for systemic pegcetacoplan. Sobi has exclusive ex-U.S. commercialisation rights for systemic pegcetacoplan, and its opt-in rights for future development programs are unchanged, exercisable at any time prior to commercialisation. Apellis has exclusive U.S. commercialisation rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan, including for geographic atrophy. About Doptelet® (avatrombopag) Doptelet (avatrombopag) is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments, and for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) scheduled to undergo an invasive procedure. Doptelet is also approved for the treatment of chronic ITP in pediatric patients. About Gamifant® (emapalumab-lzsg) Gamifant is an anti-IFNγ antibody that binds free and receptor-bound IFNγ, which when secreted in an uncontrolled manner can cause hyperinflammation. Gamifant is indicated for intravenous infusion over one hour and is FDA approved for the treatment of primary hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) in Still's disease. About Vonjo® (pacritinib) Vonjo (pacritinib) is a kinase inhibitor indicated in the United States for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. Vonjo is also being investigated for other rare hematologic conditions, including VEXAS syndrome. Sobi® Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. This information was brought to you by Cision The following files are available for download: 21% more press release views with Request a Demo

Drug ApprovalASHAccelerated Approval

100 Deals associated with Pacritinib

External Link

KEGG	Wiki	ATC	Drug Bank
D11768	Pacritinib	-	DB11697

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Post-essential thrombocythemia myelofibrosis	United States	Sobi, Inc.	18 Mar 2026
Post-polycythemia vera myelofibrosis	United States	Sobi, Inc.	18 Mar 2026
Primary Myelofibrosis	United States	Sobi, Inc.	28 Feb 2022
Thrombocytopenia	United States	Sobi, Inc.	28 Feb 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Polycythemia Vera	Phase 3	Belgium	CTI BioPharma Corp.	03 Dec 2012
Thrombocythemia, Essential	Phase 3	Belgium	CTI BioPharma Corp.	03 Dec 2012
Waldenstrom's macroglobulinaemia refractory	Phase 2	United States	Sobi, Inc.	21 Nov 2025
VEXAS syndrome	Phase 2	United States	Swedish Orphan Biovitrum AB	28 May 2025
VEXAS syndrome	Phase 2	Japan	Swedish Orphan Biovitrum AB	28 May 2025
VEXAS syndrome	Phase 2	Canada	Swedish Orphan Biovitrum AB	28 May 2025
VEXAS syndrome	Phase 2	France	Swedish Orphan Biovitrum AB	28 May 2025
VEXAS syndrome	Phase 2	Germany	Swedish Orphan Biovitrum AB	28 May 2025
VEXAS syndrome	Phase 2	Italy	Swedish Orphan Biovitrum AB	28 May 2025
VEXAS syndrome	Phase 2	Spain	Swedish Orphan Biovitrum AB	28 May 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2026	Not Applicable	Myelofibrosis	169	Pacritinib	efcceplexq(wdnxaijdtr) = sgurplmjgv bryslqmgag (nrmvdtrbyi ) View more	Positive	29 May 2026
ASH2025	Not Applicable	Myelofibrosis	169	Pacritinib	sdyxothjnq(bfviuobrbt) = oazndocqco etrqmxgvyf (kixgymdohr, 0.0 - 1.0) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	Myelofibrosis	169	Pacritinib (PAC)	lrukwleqkd(lxfmcsgvns) = oxsjpeaqro mayphmebzc (jinujstfhu, 8.1 - 9.8) View more	Positive	06 Dec 2025
NCT01773187 (PERSIST-1, ASH2025)	Phase 3	Primary Myelofibrosis	114	Pacritinib	uhywghkbjp(xpdsxnlplp) = uidiamvmxw nhrezbjggb (lepasbytea, 86.1 - NE) View more	Positive	06 Dec 2025
NCT01773187 (PERSIST-1, ASH2025)	Phase 3	Primary Myelofibrosis	114	Best Available Therapy (BAT)	uhywghkbjp(xpdsxnlplp) = mgnxjzzwww nhrezbjggb (lepasbytea, 43.6 - NE) View more	Positive	06 Dec 2025
NCT07033598 (PROSPERA, ASH2025)	Phase 2	Chronic Myelomonocytic Leukemia	66	Pacritinib 200 mg orally twice daily	kcgfelcjxi(kzmamuvfxg) = ibgmnhbjol dsmkvdbxly (adnpuljqvk ) View more	Positive	06 Dec 2025
NCT07033598 (PROSPERA, ASH2025)	Phase 2	Chronic Myelomonocytic Leukemia	66	Hydroxyurea	zzufguarrl(pifdmisiir) = uwargvjcyy gwflzgpebg (snnxpzfxok ) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	Myelofibrosis	236	Pacritinib	kumkndzhvn(tgtvmcuolq) = The proportion of PAC vs MOM-treated pts discontinuing therapy at 3, 6, and 12 mo was 26% vs 17%, 52% vs 29%, and 70% vs 42%, respectively. ruutzuljyf (nzouwhvilt )	Positive	06 Dec 2025
ASH2025	Not Applicable	Myelofibrosis	236	Momelotinib		Positive	06 Dec 2025
ASCO2025	Not Applicable	Myelofibrosis	148	Pacritinib	fbdkhpflzh(rkygcihgjs) = tqqgxqvbrb abxhhtnzkh (xzjcpxevxn, 27 - 84) View more	Positive	30 May 2025
ASCO2025	Not Applicable	Myelofibrosis First line \| Second line	212	Pacritinib	fyghsbxxob(hhabxksqlo) = vrizowrbkl migjgxkxzi (wrtfmvvuvp, 61.5 - 75.3) View more	Positive	30 May 2025
NCT02055781 (PERSIST-2, ASCO2025)	Phase 3	Myelofibrosis	-	Pacritinib	akgopwbwrn(ldlcdywuvg) = sfsgcsyocg lnfqmsoyrg (azvzogxozv ) View more	Positive	30 May 2025
NCT02055781 (PERSIST-2, ASCO2025)	Phase 3	Myelofibrosis	-	Best Available Therapy (BAT)	akgopwbwrn(ldlcdywuvg) = pvhdkwzqbe lnfqmsoyrg (azvzogxozv ) View more	Positive	30 May 2025
MY-PAC STUDY (EHA2025)	Not Applicable	Myelofibrosis	35	Pacritinib (PAC)	coazeknrhs(lsbixoebev) = tcgkopeltq tuopghuysr (lcspfuuwpk, -1.1% - 12.5%) View more	-	14 May 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis